Alpine Immune Sciences, Inc. financial data

Symbol
ALPN on Nasdaq
Industry
Pharmaceutical Preparations
Location
188 East Blaine St., Suite 200, Seattle, Washington
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Nivalis Therapeutics, Inc. (to 7/25/2017), N30 Pharmaceuticals, Inc. (to 11/25/2014)
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 581 % +65.4%
Debt-to-equity 25.7 % -61.9%
Return On Equity -41.8 % +29%
Return On Assets -11.8 % +50.9%
Operating Margin -90.9 % +64.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65.6 M shares +37.3%
Common Stock, Shares, Outstanding 65.6 M shares +37.3%
Entity Public Float 349 M USD +164%
Weighted Average Number of Shares Outstanding, Basic 64 M shares +34.6%
Weighted Average Number of Shares Outstanding, Diluted 64 M shares +34.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 56.5 M USD +119%
Research and Development Expense 83.8 M USD +14%
General and Administrative Expense 24.1 M USD +29.6%
Operating Income (Loss) -51.4 M USD +22.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -32.1 M USD +42.1%
Income Tax Expense (Benefit) 103 K USD -95.6%
Net Income (Loss) Attributable to Parent -36.8 M USD +42%
Earnings Per Share, Basic -0.64 USD/shares +63.6%
Earnings Per Share, Diluted -0.64 USD/shares +63.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 33 M USD +128%
Accounts Receivable, after Allowance for Credit Loss, Current 42 K USD -93.7%
Assets, Current 308 M USD +55.1%
Deferred Income Tax Assets, Net 0 USD -100%
Property, Plant and Equipment, Net 1.36 M USD -19.7%
Operating Lease, Right-of-Use Asset 7.32 M USD -9.12%
Assets 374 M USD +42.6%
Accounts Payable, Current 4.17 M USD +151%
Accrued Liabilities, Current 16.9 M USD +40.4%
Contract with Customer, Liability, Current 10.2 M USD -74.7%
Liabilities, Current 32.2 M USD -43.5%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 8.71 M USD -11.5%
Liabilities 40.9 M USD -55.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -263 K USD +35.4%
Retained Earnings (Accumulated Deficit) -274 M USD -15.5%
Stockholders' Equity Attributable to Parent 333 M USD +96.2%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 182 M USD +48.2%
Liabilities and Equity 374 M USD +42.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -27.7 M USD -5.88%
Net Cash Provided by (Used in) Financing Activities 19.4 M USD
Net Cash Provided by (Used in) Investing Activities -2.56 M USD -109%
Common Stock, Shares Authorized 200 M shares 0%
Common Stock, Shares, Issued 65.6 M shares +33.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.9 M USD -1101%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 33.3 M USD +126%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 63.9 M USD +16.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 65.9 M USD +15.4%
Operating Lease, Liability 9.91 M USD -8.55%
Depreciation 147 K USD +5%
Payments to Acquire Property, Plant, and Equipment 19 K USD -79.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -36.7 M USD +41.6%
Lessee, Operating Lease, Liability, to be Paid 13.8 M USD -13%
Property, Plant and Equipment, Gross 4.32 M USD +8.33%
Operating Lease, Liability, Current 950 K USD +20.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.17 M USD +2.65%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.94 M USD +2.65%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Deferred Income Tax Expense (Benefit) 155 K USD +237%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.85 M USD -22.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.22 M USD +2.63%
Deferred Tax Assets, Operating Loss Carryforwards 23.2 M USD +24.8%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) 0 USD
Current Income Tax Expense (Benefit) 0 USD
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 2.87 M USD +33.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.28 M USD +2.65%
Operating Lease, Payments 2.06 M USD +2.64%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) -4 K USD -125%
Current Federal Tax Expense (Benefit) -47 K USD -105%
Deferred Tax Assets, Net of Valuation Allowance 1.96 M USD -12.4%
Share-based Payment Arrangement, Expense 12.1 M USD +21.8%
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Interest Expense 28 K USD -92.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%